UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of October, 2019

 

Commission File Number: 001-36000

 

XTL Biopharmaceuticals Ltd.

(Translation of registrant’s name into English)

 

5 Badner St.

Ramat Gan,
4365603, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

On October 30, 2019, Oded Nagar resigned as a non-executive and external director of XTL Biopharmaceuticals Ltd. (the “Company”). Mr. Nagar’s resignation was not a result of any disagreement with the Company or its management. The Board of Directors of the Company intends to appoint Mr. Shlomo Shalev as a member of the Audit Committee and Compensation Committee.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  XTL BIOPHARMACEUTICALS LTD.
   
Date: October 31, 2019 By: /s/ Josh Levine
    Josh Levine
Chief Executive Officer

 

 

2

 

 

XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas XTL Biopharmaceuticals.
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas XTL Biopharmaceuticals.